BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline. ・In the Absence cohort, patients experienced a median 73.1% reduction in seizures. ・The DEE cohort saw a ...

Date and Time: January 6, 2026, 8AM ET Webcast: ...

Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...

The electroencephalogram (EEG) provides important information to aid clinicians in the diagnosis of epilepsy. However, EEG techniques are associated with certain limitations, as discussed in the ...

Like many teenagers, Danielle Holton's first car was a ticket to freedom. At age 17, she bought a used Hyundai wagon from her mom, paying for it with money from her job as a certified nursing ...